Simon N. Powell: Publications

Simon N. Powell: Publications


Ahmed-Seghir, S. et al. A local ATR-dependent checkpoint pathway is activated by a site-specific replication fork block in human cells. Elife 12, (2023)

Setton, J. et al. Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers. Nature 621, 129–137 (2023)

Anand, R. et al. HELQ is a dual-function DSB repair enzyme modulated by RPA and RAD51. Nature 601, 268–273 (2022)

Moore, G. et al. Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer. Mol. Cancer Res. 20, 1061–1070 (2022)

Anand, R. et al. HELQ is a dual-function DSB repair enzyme modulated by RPA and RAD51. Nature 601, 268–273 (2022)

Setton, J., Reis-Filho, J. S. & Powell, S. N. Homologous recombination deficiency: how genomic signatures are generated. Curr. Opin. Genet. Dev. 66, 93–100 (2021). Review.

Setton, Zinda, Riaz, Durocher & Zimmermann. Synthetic Lethality in Cancer Therapeutics: The Next Generation Cancer Discov. (2021). Review

Samstein, R. M. et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer 1, 1188–1203 (2021)

Pitter, K. L. et al. Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. J. Natl. Cancer Inst. 113, 266–273 (2021)

Viale, Powell & Higginson. Measuring nonhomologous end-joining, homologous recombination and alternative end-joining simultaneously at an endogenous locus in any transfectable human …. Nucleic Acids Mol. Biol. (2021)

Setton, J. et al. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. NPJ Breast Cancer 7, 135 (2021)

Hadi, K. et al. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell 183, 197–210.e32 (2020)

Setton, J. S. & Powell, S. N. Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer. Cancer research vol. 80 2085–2086 (2020). Commentary

Mandelker, D. et al. The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers. JNCI Cancer Spectr. 3, kz027 (2019)

Damerla, R. R. et al. Detection of early human Papillomavirus-associated cancers by liquid biopsy. JCO Precis. Oncol. 3, 1–17 (2019)

Leeman, J. E. et al. Human papillomavirus 16 promotes microhomology-mediated end-joining. Proc. Natl. Acad. Sci. U. S. A. 116, 21573–21579 (2019)

Bodo, S. et al. Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. J. Clin. Invest. 129, 786–801 (2019)

Jalan, M., Olsen, K. S. & Powell, S. N. Emerging Roles of RAD52 in Genome Maintenance. Cancers 11, (2019). Review

Setton, J. S. & Powell, S. N. A new role for a tumor-suppressing protein. eLife vol. 7 (2018). Commentary

Ma, J., Setton, J., Lee, N. Y., Riaz, N. & Powell, S. N. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat. Commun. 9, 3292 (2018). Review

Shen, Norton, Wen & Powell. The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. J. Natl. Cancer Inst. (2018)

Eccles, L. J., Bell, A. C. & Powell, S. N. Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks. DNA Repair 64, 1–9 (2018)

De Stanchina, Teicher, Riaz & Powell. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung CancerSLFN11 Predicts PARP Inhibitor …. Clin. Cancer Drugs (2017)

Jelinic, P. et al. The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair. Oncotarget 8, 13792–13804 (2017)

Mutter, R. W. et al. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J. Pathol. 242, 165–177 (2017)

Cuaron, J. J. et al. Exponential Increase in Relative Biological Effectiveness Along Distal Edge of a Proton Bragg Peak as Measured by Deoxyribonucleic Acid Double-Strand Breaks. International Journal of Radiation Oncology*Biology*Physics 95, 62–69 (2016)

Fridlich, R., Annamalai, D., Roy, R., Bernheim, G. & Powell, S. N. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication. DNA Repair 30, 11–20 (2015)

Lok, B. H., Carley, A. C., Tchang, B. & Powell, S. N. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene 32, 3552–3558 (2013)

Chun, J., Buechelmaier, E. S. & Powell, S. N. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol. Cell. Biol. 33, 387–395 (2013)

Bindra, R. S., Goglia, A. G., Jasin, M. & Powell, S. N. Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Res. 41, e115 (2013)

Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68–78 (2011)

Zhang, J. et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 24, 708–718 (2004)

Powell, S. N. & Kachnic, L. A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22, 5784–5791 (2003)

Xia, F. et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proceedings of the National Academy of Sciences 98, 8644–8649 (2001)

Powell, S. N. et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55, 1643–1648 (1995)